Evaluation of the immunogenicity of each of L-amino oxidase- and L-ascorbic acid-inactivated hepatitis a virus in mice as potential vaccine candidates
dc.Affiliation | October University for modern sciences and Arts (MSA) | |
dc.contributor.author | Abdullatif A.O. | |
dc.contributor.author | Tawfick M.M. | |
dc.contributor.author | Abdulall A.K. | |
dc.contributor.author | Mohamed A.F. | |
dc.contributor.other | Microbiology and Immunology Department | |
dc.contributor.other | Faculty of Pharmacy (Girls) | |
dc.contributor.other | Al-Azhar University | |
dc.contributor.other | Nasr City | |
dc.contributor.other | Cairo | |
dc.contributor.other | Egypt; Microbiology and Immunology Department | |
dc.contributor.other | Faculty of Pharmacy (Men) | |
dc.contributor.other | Al-Azhar University | |
dc.contributor.other | Nasr City | |
dc.contributor.other | Cairo | |
dc.contributor.other | Egypt; Microbiology and Immunology Department | |
dc.contributor.other | Faculty of Pharmacy | |
dc.contributor.other | October University for Modern Sciences and Arts | |
dc.contributor.other | 6th October City | |
dc.contributor.other | Giza | |
dc.contributor.other | Egypt; The Holding Company for Biological Products | |
dc.contributor.other | Vaccines and Drugs (VACSERA) | |
dc.contributor.other | Dokky | |
dc.contributor.other | Giza | |
dc.contributor.other | Egypt | |
dc.date.accessioned | 2020-01-09T20:41:41Z | |
dc.date.available | 2020-01-09T20:41:41Z | |
dc.date.issued | 2016 | |
dc.description | Scopus | |
dc.description.abstract | Hepatitis A virus (HAV) is one of the most common causes of acute viral hepatitis worldwide. Formaldehyde is the currently used inactivating agent in HAV vaccine processing despite of its adverse effects. The current study aimed to evaluate both L-amino acid oxidase (LAO) and L-ascorbic acid (LAA) as alternative inactivants for HAV and the immunogenicity of inactivated HAV in mice. Vero cell line was used for cultivation of HAV. The cytotoxicity of LAO and LAA on Vero cells was evaluated using 3-(4,5-dimethylthiazol-2-yl) 2,5 diphenyl tetrazolium bromide (MTT) assay. The immunogenicity of each LAO- and LAA-inactivated HAV was examined in parallel with reference HAV vaccine in mice. Humoral (total IgG) and cellular immune responses (IFN-? and IL-5) were evaluated in mice sera using ELISA. Both LAO and LAA could efficiently inactivate HAV within 30 and 36 hrs post treatment, respectively, at concentrations of 0.4 ?gm/ml of LAO and 1.5 mg/ml of LAA. Inactivated vaccines were immunogenic to mice on both the humoral and cellular levels. LAO prepared vaccines showed a more promising immune reactivity than LAA prepared ones and alum-adsorbed vaccines were more immunogenic than non-adjuvanted ones. In conclusion, data recorded suggest that both LAO and LAA can be used as inactivating agents for HAV grown in cell culture. LAA- and LAO-inactivated HAV can be potential vaccines as they provide effective humoral and cellular immune responses comparable to that of the reference vaccine. The stability of test vaccines is recommended to be traced at different thermal conditions, in addition to different stabilizers and different pharmaceutical formulations must be tested trying to produce a lyophilized formula for long-term stability. � Faculty of Boitechnology and Food Sciences. | en_US |
dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=21100823448&tip=sid&clean=0 | |
dc.identifier.doi | https://doi.org/10.15414/JMBFS.2016/17.6.3.937-942 | |
dc.identifier.doi | PubMed ID : | |
dc.identifier.issn | 13385178 | |
dc.identifier.other | https://doi.org/10.15414/JMBFS.2016/17.6.3.937-942 | |
dc.identifier.other | PubMed ID : | |
dc.identifier.uri | https://t.ly/L93NY | |
dc.language.iso | English | en_US |
dc.publisher | Slovak University of Agriculture | en_US |
dc.relation.ispartofseries | Journal of Microbiology, Biotechnology and Food Sciences | |
dc.relation.ispartofseries | 6 | |
dc.subject | October University for Modern Sciences and Arts | |
dc.subject | University for Modern Sciences and Arts | |
dc.subject | MSA University | |
dc.subject | جامعة أكتوبر للعلوم الحديثة والآداب | |
dc.subject | Alum | en_US |
dc.subject | Hepatitis A | en_US |
dc.subject | L-amino oxidase | en_US |
dc.subject | L-ascorbic acid | en_US |
dc.subject | Vaccine | en_US |
dc.subject | Virus inactivation | en_US |
dc.title | Evaluation of the immunogenicity of each of L-amino oxidase- and L-ascorbic acid-inactivated hepatitis a virus in mice as potential vaccine candidates | en_US |
dc.type | Article | en_US |
dcterms.isReferencedBy | Abd El-Razek, N.E.E.-D., Shoman, S.A., Mohamed, A.F., Nanocapsulated Rift Valley Fever vaccine candidates and relative immunological and histopathological reactivity in out bred Swiss mice (2011) Journal of Vaccines & Vaccination, 2 (1). , http://dx.doi.org/10.4172/2157-7560.1000115; Alyan, M.S., Shalaby, M.A., El-Sanousi, A.A., Fahmy, A., El-Sayed, M., Shebl, R.I., Antiviral and Anticancer Potentials of Snake and ScorpionVenom Derivatives (2014) Inventi Rapid: Molecular Pharmacology, 2014 (2), pp. 1-11; Alyan, M., Shalaby, M., El-Sanousi, A., El-Sayed, A., Shebl, R., New Trends in Cancer Therapy and Antiviral Drug Research (2016) International Journal of Advanced Research, 4 (5), pp. 698-710. , http://dx.doi.org/10.21474/ijar01/408; Bachmann, M.F., Bast, C., Hengartner, H., Zinkernagel, R.M., Immunogenicity of a viral model vaccine after different inactivation procedures (1994) Medical microbiology and immunology, 183 (2), pp. 95-104. , http://dx.doi.org/10.1007/bf00277160; Blackburn, N.K., Besselaar, T.G., A study of the effect of chemical inactivants on the epitopes of Rift Valley fever virus glycoproteins using monoclonal antibodies (1991) Journal of virological methods, 33 (3), pp. 367-374. , http://dx.doi.org/10.1016/0166-0934(91)90036-y; Brown, F., Review of accidents caused by incomplete inactivation of viruses (1992) Developments in biological standardization, 81, pp. 103-107; Budowsky, E.I., Friedman, E.A., Zheleznova, N.V., Principles of selective inactivation of viral genome. VII. Some peculiarities in determination of viral suspension infectivity during inactivation by chemical agents (1991) Vaccine, 9 (7), pp. 473-476. , http://dx.doi.org/10.1016/0264-410x(91)90031-z; Cederna, J.B., Klinzman, D., Stapleton, J.T., Hepatitis A virusspecific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine (1999) Vaccine, 18 (9), pp. 892-898. , http://dx.doi.org/10.1016/s0264-410x(99)00342-4; Doyle, A., Bryan, G.J., (1998) Cell and tissue culture: laboratory procedure in biotechnology, , Chicester: John Willey & Sons; Du, X.Y., Clemetson, K.J., Snake venom L-amino acid oxidases (2002) Toxicon, 40 (6), pp. 659-665. , http://dx.doi.org/10.1016/s0041-0101(02)00157-5; Ecobichon, D.J., (1997) The basis of toxicity testing, , CRC press; El-Karamany, R.M., Production in Vero cells of an inactivated rabies vaccine from strain FRV/K for animal and human use (1987) Acta virologica, 31 (4), pp. 321-328; Fiore, A.E., Wasley, A., Bell, B.P., Prevention of hepatitis A through active or passive immunization (2006) MMWR. Morbidity and Mortality Weekly Report, 55 (RR07), pp. 1-23. , http://dx.doi.org/10.1037/e566492006-001; Franco, E., Meleleo, C., Serino, L., Sorbara, D., Zaratti, L., Hepatitis A: epidemiology and prevention in developing countries (2012) World J Hepatol, 4 (3), pp. 68-73. , http://dx.doi.org/10.4254/wjh.v4.i3.68; "Hepatitis A: epidemiology and prevention in developing countries." (2012) World J Hepatol, 4 (3), pp. 68-73. , http://dx.doi.org/10.4254/wjh.v4.i3.68; Gl�ck, R., Mischler, R., Brantschen, S., Just, M., Althaus, B., Cryz, S.J., Jr., Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A (1992) Journal of Clinical Investigation, 90 (6), p. 2491. , http://dx.doi.org/10.1172/jci116141; Gupta, R.K., Aluminum compounds as vaccine adjuvants (1998) Advanced drug delivery reviews, 32 (3), pp. 155-172. , http://dx.doi.org/10.1016/s0169-409x(98)00008-8; Harrison, T.J., Dusheiko, G.M., Zuckerman, A.J., Hepatitis Viruses Principles and Practice of Clinical Virology, pp. 273-320. , http://dx.doi.org/10.1002/9780470741405.ch12; Chowdhury, P., Topno, R., Khan, S.A., Mahanta, J., Comparison of �-Propiolactone and Formalin Inactivation on Antigenicity and Immune Response of West Nile Virus (2015) Advances in virology 2015, , http://dx.doi.org/10.1155/2015/616898; Izidoro, L.F.M., Sobrinho, J.C., Mendes, M.M., Costa, T.R., Grabner, A.N., Rodrigues, V.M., Calderon, L.A., Snake venom L-amino acid oxidases: trends in pharmacology and biochemistry (2014) BioMed research international, 2014, pp. 1-19. , http://dx.doi.org/10.1155/2014/196754; Kanyenda, T.J., Abdullahi, L.H., Hussey, G.D., Kagina, B.M., Epidemiology of hepatitis A virus in Africa among persons aged 1-10 years: a systematic review protocol (2015) Systematic reviews, 4 (1), p. 1. , http://dx.doi.org/10.1186/s13643-015-0112-5; Karayiannis, P., Main, J., Thomas, H.C., Hepatitis vaccines (2004) British medical bulletin, 70 (1), pp. 29-49. , http://dx.doi.org/10.1093/bmb/ldh024; Kasai, K., Ishikawa, T., Nakamura, T., Miura, T., Antibacterial properties of l-amino acid oxidase: mechanisms of action and perspectives for therapeutic applications (2015) Applied microbiology and biotechnology, 99 (19), pp. 7847-7857. , http://dx.doi.org/10.1007/s00253-015-6844-2; Keeffe, E.B., Iwarson, S., Mcmahon, B.J., Lindsay, K.L., Koff, R.S., Manns, M., Krause, D.S., Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease (1998) Hepatology, 27 (3), pp. 881-886. , http://dx.doi.org/10.1002/hep.510270336; Lappin, M.B., Campbell, J.D.M., The Th1-Th2 classification of cellular immune responses: concepts, current thinking and applications in haematological malignancy (2000) Blood reviews, 14 (4), pp. 228-239. , http://dx.doi.org/10.1054/blre.2000.0136; Lindblad, E.B., Aluminium adjuvants in retrospect and prospect (2004) Vaccine, 22 (27), pp. 3658-3668. , http://dx.doi.org/10.1016/j.vaccine.2004.03.032; Madhusudana, S.N., Shamsundar, R., Seetharaman, S., In vitro inactivation of the rabies virus by ascorbic acid (2004) International journal of infectious diseases, 8 (1), pp. 21-25. , http://dx.doi.org/10.1016/j.ijid.2003.09.002; Mather, J.P., Roberts, P.E., (1998) Introduction to cell and tissue culture: theory and technique, , Springer Science & Business Media; Meenakshisundaram, R., Sweni, S., Thirumalaikolundusubramanian, P., Hypothesis of snake and insect venoms against Human Immunodeficiency Virus: a review (2009) AIDS research and therapy, 6 (1), p. 25. , http://dx.doi.org/10.1186/1742-6405-6-25; Mitchell, L.A., Galun, E., Rectal immunization of mice with hepatitis A vaccine induces stronger systemic and local immune responses than parenteral immunization (2003) Vaccine, 21 (13), pp. 1527-1538. , http://dx.doi.org/10.1016/s0264-410x(02)00699-0; Murata, A., Kawaaki, M., Motomatsu, H., Kato, F., Virus-inactivating effect of D-isoascorbic acid (1986) Journal of Nutritional Science and Vitaminology, 32 (6), pp. 559-567. , http://dx.doi.org/10.3177/jnsv.32.559; Rawal, B.D., Bartolini, F., Vyas, G.N., In vitro inactivation of human immunodeficiency virus by ascorbic acid (1995) Biologicals, 23 (1), pp. 75-81. , http://dx.doi.org/10.1016/1045-1056(95)90016-0; Rawal, B.D., Bartolini, F., Vyas, G.N., In vitro inactivation of human immunodeficiency virus by ascorbic acid (1995) Biologicals, 23 (1), pp. 75-81. , http://dx.doi.org/10.1016/1045-1056(95)90016-0; Reed, L.J., Muench, H., A simple method of estimating fifty per cent endpoints (1938) American journal of epidemiology, 27 (3), pp. 493-497; Sanders, B., Koldijk, M., Schuitemaker, H., Inactivated Viral Vaccines (2015) Vaccine Analysis: Strategies, Principles, and Control, pp. 45-80. , http://dx.doi.org/10.1007/978-3-662-45024-6_2, Springer Berlin Heidelberg; Sartori, A.M.C., De So�rez, P.C., Novaes, H.M.D., Amaku, M., De Azevedo, R.S., Moreira, R.C., Martelli, C.M.T., Cost-effectiveness analysis of universal childhood hepatitis A vaccination in Brazil: regional analyses according to the endemic context (2012) Vaccine, 30 (52), pp. 7489-7497. , http://dx.doi.org/10.1016/j.vaccine.2012.10.056; Shebl, R.I., Mohamed, A.F., Ali, A.E., Amin, M.A., Antimicrobial profile of selected snake venoms and their associated enzymatic activities (2012) British Microbiology Research Journal, 2 (4), p. 251. , http://dx.doi.org/10.9734/bmrj/2012/2091; Schmidtke, P., Habermehl, P., Knuf, M., Meyer, C.U., S�nger, R., Zepp, F., Cell mediated and antibody immune response to inactivated hepatitis A vaccine (2005) Vaccine, 23 (44), pp. 5127-5132. , http://dx.doi.org/10.1016/j.vaccine.2005.06.022; Stauffer, F., De Miranda, J., Schechter, M.C., Queiroz, F.A., Santos, N.O., Alves, A.M., Da Poian, A.T., New chemical method of viral inactivation for vaccine development based on membrane fusion inhibition (2007) Vaccine, 25 (46), pp. 7885-7892. , http://dx.doi.org/10.1016/j.vaccine.2007.09.025; Stauffer, F., De Miranda, J., Schechter, M.C., Queiroz, F.A., Santos, N.O., Alves, A.M., Da Poian, A.T., New chemical method of viral inactivation for vaccine development based on membrane fusion inhibition (2007) Vaccine, 25 (46), pp. 7885-7892. , http://dx.doi.org/10.1016/j.vaccine.2007.09.025; Tahaei, S.M.E., Mohebbi, S.R., Zali, M.R., Enteric hepatitis viruses (2012) Gastroenterology and Hepatology from bed to bench, 5 (1), p. 7; Turner, G.S., Inactivation of vaccinia virus by ascorbic acid (1964) Microbiology, 35 (1), pp. 75-80. , http://dx.doi.org/10.1099/00221287-35-1-75; Van Damme, P., Banatvala, J., Fay, O., Iwarson, S., Mcmahon, B., Van Herck, K., Leroux-Roels, G., Hepatitis A booster vaccination: is there a need? (2003) The lancet, 362 (9389), pp. 1065-1071. , http://dx.doi.org/10.1016/s0140-6736(03)14418-2; Van Damme, P., Thoelen, S., Cramm, M., De Groote, K., Safary, A., Meheus, A., Inactivated hepatitis A vaccine: Reactogenicity, immunogenicity, and long-term antibody persistence (1994) Journal of medical virology, 44 (4), pp. 446-451. , http://dx.doi.org/10.1002/jmv.1890440425; Vidor, E., Dumas, R., Porteret, V., Bailleux, F., Veitch, K., Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data (2004) European Journal of Clinical Microbiology and Infectious Diseases, 23 (4), pp. 300-309. , http://dx.doi.org/10.1007/s10096-003-1094-0; Wang, C.H., Tschen, S.Y., Heinricy, U., Weber, M., Flehmig, B., Immune response to hepatitis A virus capsid proteins after infection (1996) Journal of clinical microbiology, 34 (3), pp. 707-713. , http://dx.doi.org/10.1016/0264-410x(95)00152-q; White, L.A., Freeman, C.Y., Forrester, B.D., Chappell, W.A., In vitro effect of ascorbic acid on infectivity of herpesviruses and paramyxoviruses (1986) Journal of clinical microbiology, 24 (4), pp. 527-531; White, L.A., Freeman, C.Y., Forrester, B.D., Chappell, W.A., In vitro effect of ascorbic acid on infectivity of herpesviruses and paramyxoviruses (1986) Journal of clinical microbiology, 24 (4), pp. 527-531; Wu, D., Guo, C.Y., Epidemiology and prevention of hepatitis A in travelers (2013) Journal of travel medicine, 20 (6), pp. 394-399. , http://dx.doi.org/10.1111/jtm.12058; Zedan, M.A., Mohamed, F.A., Tantawy, H.M., Amal, S.M., Comparative Evaluation of different enhancers to liquid Rabies vaccine at different thermal conditions (2003) Egypt. J. Zool, 40, pp. 443-453 | |
dcterms.source | Scopus |